The buzz about bigger-and-better cancer drug sales abounds at the American Society of Clinical Oncology's annual meeting. But which oncology meds are actually tipped to make major gains between now and the end of the decade?
An Australia government proposal to trim the national drug-coverage budget for innovative drugs by 5%, or U.S.$2.36 billion, has invited a juggernaut of industry opposition already descending on the parliament. The reductions are aimed at the nation's leading drugs, including those for cancer.
Now that Valeant has officially nabbed Dendreon's cancer vaccine Provenge, the Canadian drugmaker will have to nurse the treatment to health.
Authorities in Europe have added two Roche cancer drugs to their list of stolen meds that wholesalers and healthcare providers should be on the lookout for. That brings the tally to 5 drugs that the European Medicines Agency says should be closely examined for signs of tampering.
Last week, drugmaker Hikma struck a deal to buy some of the sterile injectable assets of a Boehringer Ingelheim unit to expand in that growing part of the industry. Now, U.S.-based Amneal Pharmaceuticals is looking to India for a chance to exploit that niche of the market.
IMS Health has found that a group of cancer treatments launched over the past three years "are following the same trajectory" as blockbusters such as Roche's Avastin, Novartis' Gleevec, Bayer's Nexavar, and Merck Serono's Erbitux--at least so far.
Labels on shipments to a St. Louis, MO, suburb, arranged by two men from Turkey said they contained "gifts" and "documents." Instead, federal prosecutors and the FDA said the shipments were illegal, and sometimes counterfeit, cancer drugs being smuggled in from outside the U.S.
The feds have taken another drug dealer off the streets. This one sold more than $7 million worth of unapproved foreign cancer drugs from Turkey, Pakistan, India, and elsewhere to oncologists who were administering them to their patients.
Taiwan's TOT Biopharm has opened in mainland China the first phase of what it says is a $100 million plant for developing and manufacturing cancer drugs for the global market.
Canada's Sunshine BioPharma has tabbed CMO Beta Pharma to manufacture and help develop its developmental breast cancer treatment, Adva-27a.